Evidence map›Paper›PMID 35625843›Full record

ReviewBiomedicines2022

Signaling Pathways Regulating the Expression of the Glioblastoma Invasion Factor

María Carcelen, Carlos Velasquez, Verónica Vidal, Olga Gutiérrez, José L Fernández-Luna

Open access · goldAbstract readReview
In one paragraph

Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

María CarcelenInstituto de Investigación Vadecilla (IDIVAL), 39011 Santander, Spain.
Carlos VelasquezInstituto de Investigación Vadecilla (IDIVAL), 39011 Santander, Spain.
Verónica VidalInstituto de Investigación Vadecilla (IDIVAL), 39011 Santander, Spain.
Olga GutiérrezInstituto de Investigación Vadecilla (IDIVAL), 39011 Santander, Spain.
José L Fernández-LunaInstituto de Investigación Vadecilla (IDIVAL), 39011 Santander, Spain.
Instituto de Investigación Marqués de Valdecilla · ESMarqués de Valdecilla University Hospital · ES

Funding

Instituto de Investigación Marqués de Valdecilla APG/03Instituto de Salud Carlos III PI17/01399
6 · The paper itself

Abstract

Glioblastoma (GBM) is one of the most aggressive cancers, with dismal prognosis despite continuous efforts to improve treatment. Poor prognosis is mostly due to the invasive nature of GBM. Thus, most research has focused on studying the molecular players involved in GBM cell migration and invasion of the surrounding parenchyma, trying to identify effective therapeutic targets against this lethal cancer. Our laboratory discovered the implication of TENM1, also known as ODZ1, in GBM cell migration in vitro and in tumor invasion using different in vivo models. Moreover, we investigated the microenvironmental stimuli that promote the expression of TENM1 in GBM cells and found that macrophage-secreted IL-6 and the extracellular matrix component fibronectin upregulated TENM1 through activation of Stat3. We also described that hypoxia, a common feature of GBM tumors, was able to induce TENM1 by both an epigenetic mechanism and a HIF2α-mediated transcriptional pathway. The fact that TENM1 is a convergence point for various cancer-related signaling pathways might give us a new therapeutic opportunity for GBM treatment. Here, we briefly review the findings described so far about the mechanisms that control the expression of the GBM invasion factor TENM1.

Indexed as

cell migrationglioblastomaHIF2αhypoxiaODZ1promoter methylationStat3tumor invasion

Identifiers

PMID35625843
PMCPMC9138594
OpenAlexW4280615906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.